CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CELZ evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CELZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CELZ
Creative Medical Technology Holdings, Inc. (CELZ) is a clinical-stage biotechnology company developing stem cell-based therapies, with a lead candidate CELZ-201 in a Phase I/II trial for chronic lower back pain, and has recently completed a best-efforts public offering to fund its clinical programs.
Key risk: Uncertain funding from offering
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..
Similar companies
Creative Medical Technology Holdings, Inc. (CELZ) is a clinical-stage biotechnology company developing stem cell-based therapies, with a lead candidate CELZ-201 in a Phase I/II trial for chronic lower back pain, and has recently completed a best-efforts public offering to fund its clinical programs.
- Lead product candidate CELZ-201 is in a Phase I/II clinical trial for chronic lower back pain, with a fourth cohort of patients being enrolled [sec · filed 2026-06-25].
- In November 2024, an independent Data Safety Monitoring Board (DSMB) completed an interim safety review of the CELZ-201 ADAPT trial, concluding that safety data from the first five dosed patients was acceptable [sec_mda · as of 2025-11-07].
- The company utilizes AI in drug discovery to accelerate target identification and biological screening, and collaborates with Greenstone Biosciences Inc. for development opportunities [sec_mda · as of 2025-11-07].
- As of June 30, 2026, the company reported cash and equivalents of $8.7 million, zero revenue, a net loss of $1.5 million, and shareholders' equity of $6.3 million [sec].
- The company completed a best-efforts public offering of common stock and warrants in June 2026, with net proceeds intended to fund the CELZ-201 clinical trial, though the final amount is not yet determinable [sec · filed 2026-06-25].
What works
- The company has successfully passed an independent DSMB safety review for its lead candidate CELZ-201, indicating early safety data is acceptable [sec_mda · as of 2025-11-07].
- The company leverages AI in drug discovery to potentially shorten development timelines and collaborates with partners like Greenstone Biosciences to expand opportunities without diverting from core programs [sec_mda · as of 2025-11-07].
What to weigh
- The company has no revenue and continues to realize losses from operations, with a net loss of $1.5 million for the quarter ended June 30, 2026 [sec].
- The best-efforts public offering has no minimum offering amount, meaning the actual net proceeds may be substantially less than anticipated, creating uncertainty in funding for clinical trials [sec · filed 2026-06-25].
- Research and development expenses decreased by 11% in the nine months ended September 30, 2025, compared to the prior year, partly due to reduced spending on the Type I Diabetes (CELZ-201 CREATE-1) clinical trial [sec_mda · as of 2025-11-07].
From the filings
Quoted directly from source documents.
The company's lead candidate CELZ-201 is in a Phase I/II trial for chronic lower back pain, with a fourth cohort being enrolled.
“complete the clinical study of the fourth cohort of patients enrolled in our Phase I/II clinical trial for the treatment of chronic lower back”
SEC filings · June 25, 2026
An independent DSMB completed an interim safety review of the CELZ-201 ADAPT trial, concluding safety data from the first five patients was acceptable.
“In November 2024, we announced the successful completion of an independent interim safety review by the Data Safety Monitoring Board (DSMB) of our CELZ-201 ADAPT clinical trial. The DSMB reviewed safety data from the first five dosed patients concluding that th”
SEC MD&A · November 7, 2025
The company uses AI in drug discovery to accelerate development.
“In drug discovery, AI accelerates the identification of potential targets and optimizes biological screenings, significantly shortening development timelines.”
SEC MD&A · November 7, 2025
The best-efforts offering has no minimum offering amount, so net proceeds may be substantially less than maximum amounts.
“However, because this is a best efforts offering and there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, Placement Agent's fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus.”
SEC filings · June 25, 2026
Risks & what to watch (3)›
Key risks
- Uncertain funding from offering — Best-efforts offering with no minimum may yield substantially less net proceeds than expected, impacting clinical trial funding [sec · filed 2026-06-25].
- No revenue and ongoing losses — Company has zero revenue and continues to incur net losses, with $1.5M net loss in Q2 2026 [sec].
- Clinical trial risk — Phase I/II trial for CELZ-201 is still enrolling patients; no efficacy data or regulatory approval yet [sec · filed 2026-06-25].
What to watch
- Completion of enrollment and results from the fourth cohort of the CELZ-201 Phase I/II clinical trial for chronic lower back pain [sec · filed 2026-06-25].
- Final net proceeds from the June 2026 best-efforts public offering and their impact on cash runway [sec · filed 2026-06-25].
- Any updates on collaboration with Greenstone Biosciences or other partners for development acceleration [sec_mda · as of 2025-11-07].
- Future regulatory filings or approvals for CELZ-201 or other pipeline candidates [sec · filed 2026-06-25].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
17.9 months
D/E 0.08
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
10
Total value held
$237K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 40,700 | $84K |
| geode capital management, llc | 38,290 | $79K |
| xtx topco ltd | 14,260 | $29K |
| susquehanna international group, llp | 10,469 | $22K |
| vanguard fiduciary trust co | 5,518 | $11K |
| wells fargo & company/mn | 5,000 | $10K |
| morgan stanley | 534 | $1K |
| fmr llc | 250 | $515 |
| ubs group ag | 1 | $2 |
| sbi securities co., ltd. | 1 | $2 |
Short Interest
as of May 20, 2026- % of float
- 4.3%
- Days to cover
- 2.5
- Shares short
- 156,760
- Daily short volume (May 21, 2026)
- 41.7%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CELZ short interestGovernance
Frequently asked questions
What is the AI investment thesis for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.?
Creative Medical Technology Holdings, Inc. (CELZ) is a clinical-stage biotechnology company developing stem cell-based therapies, with a lead candidate CELZ-201 in a Phase I/II trial for chronic lower back pain, and has recently completed a best-efforts public offering to fund its clinical programs.
What is CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s lead drug candidate?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s most advanced tracked candidate is celz-100 (Preclinical) for Chronic Back Pain; Chronic Low-back Pain.
Who is the CEO of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.?
Mr. Timothy Warbington is the chief executive officer of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ).
Where is CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. headquartered?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) is headquartered in Phoenix, AZ, United States.
What therapeutic areas does CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. focus on?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. develops therapies across Metabolic, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.